香港大医院pd1药物费用多少钱，Keytruda药物哪里可以买到

Non-Small Cell Lung Cancer非小细胞肺癌

NCCN Guidelines Version 4.2016 NCCN指南2016第4版

Discussion 讨论

Treatment Approaches 治疗手段

Targeted Therapies 靶向治疗

Pembrolizumab 派姆单抗(Keytruda健痊得, 默沙东)

瑞斯国际健康hpv2030香港杏泽医疗如何会诊

很多家属对订购香港PD1的流程不太清楚，下面瑞斯国际pd1就给大家详细讲解一下如何购香港PD1流程和如何安排会诊事项了。由于治疗癌症的新药PD1属于处方药物所以必须经过香港医生的会诊流程才能够购置。会诊分为三种类型：书面会诊、远程视频会诊、面诊会诊。

书面会诊指的是病人家属把患者的诊断、治疗、复查等资料拍照发香港医生进行会诊看病人能否用药PD1。只有符合用药要求的才能订购。书面会诊优势：费用最低可以2-3天就知道可否用药条件，如果直接去香港面诊不符合用药要求那么也就意味着白跑一趟。

远程视频会诊指的是病人或者家属通过远程视频连线香港医生进行15分钟会诊来明确病人到底能不能用药PD1以及具体用K药还是O药。视频会诊特点：效率较高可以会诊完就知道到底能不能用药，但是费用较高预估3000-4000港币。

The NCCN Panel recommends pembrolizumab (category 1) as subsequent therapy for patients with metastatic non-squamous or squamous NSCLC and PD-L1 expression. NCCN小组推荐派姆单抗（1类）作为转移性非鳞或鳞型NSCLC并且表达PD-L1患者的后续治疗。

For the 2016 update (Version 4), the NCCN Panel revised the recommendation for pembrolizumab to category 1 (from category 2A) as subsequent therapy based on the randomized phase 2/3 trial (KEYNOTE-010).

基于随机2/3期试验（KEYNOTE-010），2016第4版更新，NCCN小组将派姆单抗作为后续治疗推荐从2A类修改为1类。

Previously (Version 1), the NCCN Panel had a category 2A recommendation for pembrolizumab based on the phase 1 KEYNOTE-001 trial and FDA approval.

基于1期KEYNOTE-001试验和FDA的批准，之前的第1版，NCCN小组将派姆单抗列为2A类推荐。

In addition, the NCCN Panel recommends immune checkpoint inhibitors, such as pembrolizumab and nivolumab, as preferred agents for subsequent therapy.

此外，NCCN专家组推荐免疫检查点抑制剂，如派姆单抗和尼鲁单抗作为后续治疗的首选药物。

As previously mentioned, human immune-checkpoint--inhibitor antibodies inhibit the programmed death (PD-1) receptor, which improves antitumor immunity; PD-1 receptors are expressed on activated cytotoxic T-cells.

如前所述，人类免疫检查点抑制剂抗体抑制程序性死亡（PD-1）受体，从而改善抗肿瘤免疫；在活化的细胞毒性T细胞上表达PD-1受体。

A recent randomized phase 2/3 trial (KEYNOTE-010) assessed pembrolizumab in patients with previously treated advanced non-squamous and squamous NSCLC who were PD-L1 positive (≥ 1%); most were current or former smokers.

最近一项随机2/3试验（KEYNOTE-010）评估了派姆单抗治疗既往治疗过的、PD-L1阳性的晚期非鳞和鳞型NSCLC患者（≥1%）；大部分都是当前或既往吸烟者。

There were 3 arms in this trial: pembrolizumab at 2 mg/kg, pembrolizumab at 10 mg/kg, and docetaxel at 75 mg/m2 every 3 weeks.

在这项试验中有3组：派姆单抗2mg/kg、派姆单抗10mg/kg、多西他赛75mg/㎡每3周1次。